Abstract. Associations of functional single nucleotide polymorphisms in cytochrome P450 1B1, epoxide hydrolase 1, NAD(P)H:quinone oxidoreductase 1, glutathione S-transferase Pi-1 and deletions of glutathione S-transferases Mu-1 and ı-1 with colorectal cancer risk were investigated in a hospital-based case-control study on 495 matched pairs of Czech Caucasians. Polymorphisms were assessed by polymerase chain reaction restriction fragment length polymorphism-based methods, allele-specific multiplex and allelic discrimination by real-time polymerase chain reaction. Carriers of variant Ser allele in codon 453 of cytochrome P450 1B1 (rs1800440) were at a significantly lower risk of colorectal cancer compared to carriers of the wild-type allele (adjusted odds ratio, aOR=0.68, CI=0.51-0.89, p=0.006). The combination of polymorphisms in codons 453 and 432 (rs1056836) of cytochrome P450 1B1 further increased the protective effect (aOR=0.53, CI=0.34-0.83, p=0.005). The glutathione S-transferase Mu-1 deletion was associated with a moderately elevated colorectal cancer risk (aOR=1.30, CI=1.01-1.68, p=0.044). Combination of glutathione Stransferase Mu-1 and ı-1 deletion was associated with a significantly higher colorectal cancer risk compared to the presence of both full-length genes (aOR=1.58, CI=1.01-2.47, p=0.044). Genetic polymorphisms in glutathione Stransferase Pi-1, NAD(P)H:quinone oxidoreductase 1, epoxide hydrolase 1 and deduced epoxid hydrolase 1 activity did not modify the risk of colorectal cancer. These results provide further evidence that interaction between metabolic gene variants contributes to colorectal carcinogenesis.
Introduction
Worldwide, colorectal cancer (CRC) is the third most common cancer with an estimated 1,023,256 newly diagnosed cases and 529,020 deaths per year (1) . In terms of CRC incidence, the Czech Republic ranks second in Europe (2) and the number of new cases is rapidly increasing (3) . It is postulated that 20-30% of all patients with CRC have a family history of CRC that suggests a genetic contribution, common exposures among family members, or a combination of both (4) . Red meat consumption has frequently shown an association with an increased risk of CRC. It has been proposed that this risk may be due to carcinogenic polycyclic aromatic hydrocarbons (PAHs) and heterocyclic amines produced when meat is cooked at high temperatures (5) . These chemicals, aromatic amines and nitroso compounds may be found in tobacco smoke which is also recognized as a potential CRC risk factor (6) . Metabolism of these chemicals is performed by the genetically variable xenobiotic-metabolizing enzymes (XME). Briefly, phase I XME such as cytochromes P450 (e.g. CYP1B1), epoxide hydroxylases (e.g. EPHX1) or oxidoreductases (e.g. NQO1) produce reactive metabolites which are then conjugated by transferases (e.g. GSTM1, GSTP1, GSTT1) to polar compounds in phase II reactions. Phase II metabolites may be further processed (metabolism, cleavage, hydrolysis, acetylation, etc.) by phase III XME (7) . Genetic polymorphisms in XME genes that alter the expression and activity of the protein products are thus strong candidates for CRC risk modifiers. ONCOLOGY REPORTS 24: 1347 -1353 Association between exposure-relevant polymorphisms in CYP1B1, EPHX1, NQO1, GSTM1, GSTP1 and GSTT1 and risk of colorectal cancer in a Czech population Cytochromes P450 (CYPs) are the most important enzymes involved in the phase I of biotransformation. CYPs catalyze a large number of reactions modifying dietary and smoking-derived pre-carcinogens and participate in the metabolism of endogenous compounds including hormones and bile acids (8) . CYP1B1 plays an important role in activating PAHs or heterocyclic amines to reactive metabolites that cause DNA damage. Polymorphisms in CYP1B1 have recently been associated with CRC susceptibility (9) . Epoxide hydrolase (EPHX1) catalyzes the hydrolysis of major metabolites of PAHs (epoxides) to less reactive trans-dihydrodiols. Two common alleles of EPHX1 in codons 113 (site T337C, amino acid change Tyr113His, dbSNP: rs1051740) and 139 (A415G, His139Arg, rs2234922) affect enzyme activity (10) . However, a lack of association of EPHX1 polymorphisms with CRC risk has been reported (11, 12) . NAD(P)H:quinone oxidoreductase (NQO1) is an obligate two-electron reductase that can either bioactivate or detoxify quinones and may play an important role in chemoprevention (13) . An NQO1 polymorphism in codon 187 (C609T, Pro187Ser, rs1800566), resulting in an inactive enzyme, has been associated with the risk of CRC (12, 14) and sporadic distal colorectal adenomas (15) . Glutathione S-transferases (GST), GSTM1, GSTP1 and GSTT1 belong to the most frequently studied XMEs in molecular epidemiology of cancer. Large genomic deletions (null genotype) of GSTM1 and GSTT1 result in a complete lack of enzyme activities. A GSTP1 polymorphism in codon 105 (A313G, Ile105Val, rs1695) generates an enzyme with different heat stability and substrate affinity (16) . A study by Ferraz et al (17) suggested that GSTT1 and GSTP1 could play a role in the occurrence of KRAS and TP53 mutations in CRC and a report by Moore et al (18) showed associations between colorectal adenomas and GSTM1-plus and GSTT1-null among smokers. Recently, we have reported an association of combined EPHX1, GSTM1 and GSTT1 polymorphisms with genetic damage (higher DNA single-strand breaks) in general Czech population (19) .
This study evaluated associations between polymorphisms in CYP1B1, EPHX1, NQO1, GSTM1, GSTP1, GSTT1 and risk of CRC in a relatively homogeneous population with one of the highest CRC incidences.
Materials and methods
Subjects. The study population comprised 495 patients with CRC (cases) and 495 individuals with no evidence of colorectal malignancy (controls). Eligibility criteria for study participation of cases and controls included Czech origin, ages 29 years or more, and consent to provide biological samples for genetic analysis. To reduce selection bias, only those subjects with no previous diagnosis were included in the study to avoid inclusion of patients with chronic diseases who may be repeatedly admitted to hospital and modify their habits because of their disease. Recruitment (20) . Four hundred and fifty-seven cases were excluded because eligibility criteria were not met or incomplete lifestyle and potential risk factor information was available or biological material was lacking.
Controls were recruited over the same period as the cases from individuals undergoing colonoscopy for various gastrointestinal complaints (macroscopic bleeding, positive fecal occult blood test, hemorrhoids, abdominal pain of unknown origin) from five large gastroenterological departments (Prague, Brno, Jihlava, Liberec, and Pribram). Due to the high incidence of CRC in the Czech Republic, colonoscopy is highly recommended and widely practiced. Controls were selected from those showing negative colonoscopy results for malignancy or idiopathic bowel diseases. Controls had no diagnosis of chronic disease necessitating repeated admittance to hospital (21) . One hundred and ninety-three controls were excluded because eligibility criteria were not met or incomplete lifestyle and potential risk factor information was available or biological material was lacking. In the last step, controls were matched on the basis of age (±2.5 years) to cases and thus 495 case-control pairs were established for this study. Study subjects provided by self-guided questionnaire information on their education, living area, lifestyle habits, body mass index (BMI), diabetes, family/personal history of cancer and long-term (at least 6 consecutive months) drug use. The case-control set was not collected specifically for the present study, but for previous studies on the risk of genetic polymorphisms in different pathways, as recently described (21) .
All subjects were informed and gave written consent to participate in the study. The design of the study was approved by the Ethics Committee of the Institute of Experimental Medicine, Prague, Czech Republic.
Genotyping. Blood was collected during diagnostic procedures using tubes with K 3 EDTA anticoagulant. DNA was isolated from lymphocytes using the phenol/chloroform extraction method as described earlier (22) . Polymorphisms in CYP1B1 (Leu432Val, dbSNP: rs1056836 and Asn453Ser, rs1800440), GSTM1 (gene deletion) and GSTT1 (gene deletion) were assayed by published methods: polymerase chain reaction (PCR) restriction fragment length polymorphism and allelespecific multiplex PCR (23) . Oligonucleotide primers were synthesized by Generi Biotech (Hradec Kralove, Czech Republic). Polymorphisms in GSTP1 (Ile105Val, rs1695), NQO1 (Pro187Ser, rs1800566) and EPHX1 (His113Tyr, rs1051740 and Arg139His, rs2234922) were assayed by allelic discrimination with TaqMan Drug Metabolism Genotyping Assays (Applied Biosystems, Foster City, CA) using real time PCR in RotorGene 6000 (Corbett Research, Brisbane, Australia). The TaqMan assays (GSTP1, Ile105Val, C-3237198_20; NQO1, Pro187Ser, C-2091255_30; EPHX1, His113Tyr, C-14938_30 and Arg139His, C-11638783_30) were performed according to manufacturer's instructions (Applied Biosystems). EPHX1 enzyme activity was inferred according to the results of His113Tyr and Arg139His genotyping (22) . For quality control, 10% of the samples were randomly selected and re-genotyped with 100% concordance of the results.
Statistical analysis.
In the first round of analyses, HardyWeinberg equilibrium was assessed for the control group. The distribution of genotypes did not significantly deviate from equilibrium. The differences in distribution of the genotypes between cases and controls were assessed from 2x2 tables and Pearson's ¯2 test was used to test significance. We further employed binary logistic regression to model the association between the risk of CRC and the studied genotypes and their combinations while adjusting for the effects of the age at recruitment, sex, BMI, smoking, alcohol consumption, living area and education. The two-sided p<0.05 was considered statistically significant. Analyses were performed using Win SPSS v13.0 (SPSS, Chicago, IL). Our study had 85% power to detect odds ratio (OR) 1.5 at ·=0.05 for the 0.15 rare allele frequency of CYP1B1 codon 453 (the lowest frequency from the analyzed polymorphisms). The rest of the studied polymorphisms had higher power to detect this OR.
Results
Characteristics of study population. This case-control study is based on a comparison of 495 CRC cases and 495 controls. Basic characteristics and crude comparison of the cases and controls with respect to the potential confounders are given in Table I . The cases and controls differ significantly in their smoking status, education and living area. Despite the effort to match the controls and cases for age, the controls tend to be slightly younger than the cases (mean difference 1.7 years, p=0.036). A biological significance of this age difference is unlikely; nevertheless, when evaluating the effects of studied genotypes and their combinations on the CRC risk, we accounted for age and for effects of the other potential risk factors by means of the binary logistic regression.
Associations of polymorphisms and selected gene combinations with colorectal cancer risk. The summary of crude and adjusted odds ratios (cOR and aOR), 95% confidence intervals (CI) and corresponding p-values is given in Tables II  and III . Carriers of the variant Ser allele in codon 453 of CYP1B1 were at significantly lower risk of CRC than the carriers of the wild-type (cOR=0.74, 95% CI=0.56-0.96, Table I . Characteristics of the studied population. 
Percentages in brackets. a Pearson¯2 test; cOR, crude odds ratio; 95% CI, 95% confidence interval; b increase of risk per one unit change in age at recruitment; c ANOVA test.
- Table II . Associations of polymorphisms in CYP1B1, EPHX1, NQO1, GSTM1, GSTT1 and GSTP1 with colorectal cancer risk. 
------------------------------------------------------------------------------------------------------------
Number of genotype carriers presented (percentages in brackets). a Crude odds ratios (cOR) and 95% confidence intervals (95% CI); b odds ratios (aOR) and 95% confidence intervals (95% CI) adjusted for age at diagnosis, gender, smoking, education and living area; c frequency of variant allele carriage in studied subgroups; d carriers of at least one variant allele in codons 432 and 453.
- ---------------------------------------------------------------------------------------------------------------p=0 .025, Table II ). The protective effect was more apparent, when the carriers of the wild-type genotype in both codons 432 and 453 of CYP1B1 were combined and compared to carriers of the variant alleles in these codons (cOR=0.55, 95% CI=0.36-0.84, p=0.005, Table II ). The adjusted analyses of the polymorphism in codon 453 of CYP1B1 and the codon 432-453 diplotype also showed significant associations with CRC risk (aOR=0.68, 95% CI=0.51-0.89, p=0.006 and aOR=0.53, 95% CI=0.34-0.83, p=0.005, respectively, Table II ). The deletion of GSTM1 was associated with a moderate increase in the CRC risk (cOR=1.23, 95% CI=0.96-1.58, p=0.098, Table II ). This association reached the level of statistical significance after adjustment (aOR=1.30, 95% CI=1.01-1.68, p=0.044, Table II ). Neither genetic polymorphisms in EPHX1, NQO1, GSTP1 and GSTT1 nor the inferred EPHX1 activity modified CRC risk (results not shown). In agreement with our previous studies (19, 22) , the effect of functionally-relevant combinations of polymorphisms in GSTs and EPHX1 was also analyzed. Of the analyzed combinations (GSTM1-GSTT1, GSTM1-GSTP1, GSTT1-GSTP1, GSTM1-EPHX1-activity, GSTT1-EPHX1-activity, and GSTP1-EPHX1-activity), none were significantly associated with the CRC risk in crude analyses (Table III) . However, adjusted analyses showed a significantly higher risk in individuals carrying the combination of GSTM1-null and GSTT1-null genotype when compared to GSTM1-plus and GSTT1-plus carriers (aOR=1.58, 95% CI=1.01-2.47, p=0.044, Table III ). Smoking did not modify the observed effects of any studied polymorphisms (results not shown).
Discussion
The Czech Republic has one of the highest CRC incidences worldwide. Possible factors contributing to the high CRC incidence in the Czech Republic may involve dietary habits, e.g. high content of fat containing diet based on fried and roasted pork meat (24) , relatively homogeneous genetic background (25) , and a good capture of CRC cases due to well established cancer registry.
The major purpose for defining genetic markers associated with cancer disease is to target preventive screening programs to high-risk individuals (FOBT, colonoscopy or flexible sigmoidoscopy in CRC) and interventions to prevent the development of cancer (dietary changes, cessation of smoking, avoidance of obesity). The study of association of XME polymorphisms with cancer needs to be controlled very carefully in terms of exposure, age and gender of participants (23, 26) . This was our primary focus during the statistical analyses. Most of the variables (age, gender, BMI and smoking) included in our statistical analyses as potential confounders are so-called obligatory confounders in the field of cancer epidemiology (27) (28) (29) . Education was included as a surrogate measure for socio-economic status of study participants, which is also considered to be potentially important confounder. The living area (urban vs. rural) was selected as a surrogate measure of some features of lifestyle and environmental exposures. In the Czech Republic, both living area and education are commonly used for this purpose (30) . We have used the colonoscopy-negative control group to ensure disease-free control individuals, as a negative colonoscopy result serves as the best available proof of the absence of CRC (31) .
Variant allele frequencies of the studied XME polymorphisms in the control group did not significantly differ from previously published data from the Czech population (22, 23) . Polymorphisms in EPHX1 (neither single polymorphisms nor their combinations which serve for enzyme activity deduction), GSTP1 and NQO1 did not modify CRC risk. The results Table III . Associations of combinations of polymorphisms in EPHX1, GSTM1, GSTT1 and GSTP1 with colorectal cancer risk. 
obtained in this study correspond to some previous studies [EPHX1, negative results (11, 12, 15) ] but do not confirm findings published by others [EPHX1 as a CRC protective factor; (32) and NQO1 as a CRC risk factor (12, 14, 33) ]. It is generally true that population-specific genetics and/or lifestyle differences together with variations in study design, study power and methodology may cause discrepancies among case-control studies. It is essential to reproduce results on adequate samples sizes from ethnically well-defined populations.
In our study, GSTM1-null genotype increased the CRC risk 1.3-fold alone and 1.6-fold in combination with the inheritance of GSTT1-null genotype. Similarly to our study, GSTM1-null and GSTT1-null genotypes were identified as CRC risk factors (OR=1.62, CI=1.06-2.46 and OR=1.64, OR=1.10-2.59, respectively) in the Turkish population (34) . The combination of polymorphism in GSTP1 with GSTM1-null was associated with higher CRC risk in a Japanese study (35) . Elevation in CRC risk by inheritance of the GSTM1-null allele (OR=1.41) was also observed amongst UK CRC patients, although this effect did not reach statistical significance (36) . However, no association of GSTM1 or GSTT1 with CRC risk was observed in the Scottish population (37) . The combination of GSTM1 and GSTT1 deletions was associated with higher risk of developing a transverse or rectal tumor (34) . Functional study on 208 German individuals, who underwent colonoscopy, observed significant decrease in GST activity, GSH levels and GSTP1 expression from proximal to distant colon (38) . Moreover, GSTP1 seems highly relevant for CRC therapy as the GSTP1 polymorphism in codon 105 was associated in a dose-dependent fashion with increased survival of patients with advanced CRC receiving 5-FU/ oxaliplatin chemotherapy (39) . Thus, in addition to the relevance for predictive testing, there may be a role of variants in XME genes as predictive therapeutic markers.
A study of Huang et al (40) on African Americans and American Caucasians found that GSTT1 and GSTM1 polymorphisms may be slightly related to the CRC risk and that there may be ethnic differences in gene-smoking interactions. However, our study in the Czech population did not find any modifying effect of smoking. According to the study of Skjelbred et al (41) , GSTM1, GSTP1 and EPHX1 may modify the effect of dietary factors on the risk of developing CRC and colorectal adenoma. Moore et al (18) published the association between advanced villous colorectal adenomas (precursors of CRC) and GSTM1-plus and GSTT1-null in smokers. A recent meta-analysis supports the role of GSTM1-null as a potential CRC risk factor, especially in Caucasian populations (42) . Published results along with our data suggest that colorectal carcinogenesis may be partly driven by interaction between XME and environmental factors. The exact nature of these interactions needs to be studied in detail. Moreover, various populations and subpopulations might have a higher CRC risk and the underlying mechanisms may differ.
Carriers of the variant allele in codon 453 of CYP1B1 (rs1800440) indicated a lower CRC risk. Analysis of the CYP1B1 diplotype further underlined this effect. Our study adds additional information to recently reported observations. CYP1B1 was found to be a CRC risk associated gene by Bethke et al (43) . Fan et al (44) suggested a significant interaction between CYP1B1 and cigarette smoking in a CRC case-only study in the Chinese population. Furthermore, the association between CRC risk and polymorphisms in CYP1B1 (and also CYP1A1 and CYP1A2) was observed in the case-control study of Landi et al (45) . Although we identified the rs1800440 polymorphism in CYP1B1 as a potential CRC risk-associated allele, the two previously published studies did not associate this SNP with CRC risk (43, 45) . Conflicting results of these case-control studies may be due to unknown interactions with environmental or other genetic factors and may vary according to the choice of polymorphisms to be genotyped. Bandiera et al (46) demonstrated that P450 1B1-Ser453 protein displays lower intracellular protein levels and is degraded more rapidly than the other P450 1B1 variants. They concluded that it is probable that individuals with the CYP1B1-Ser453 allele have reduced metabolic activation of some endogenous (e.g. estrogens) and exogenous (e.g. PAHs or heterocyclic amines) carcinogens. Indeed, carriers of the variant CYP1B1 Ser/Ser genotype in codon 453 showed a significantly reduced incidence of endometrial cancer compared with homozygotes who carried Asn at this position (OR=0.62; 95% CI=0.43-0.91) (47) .
In conclusion, our study identified polymorphisms in CYP1B1, GSTM1 and GSTT1 as modifiers of CRC risk in the Czech population. If verified by independent studies, these polymorphisms might be used for identification of high-risk individuals. Preventive screening programs and interventions to prevent the development of CRC could then be targeted to these individuals.
